Trial Profile
Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naive Patients With Advanced or Recurrent Non-squamous NSCLC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Innovent Biologics
- 18 Jun 2020 According to an Innovent Biologics media release, BYVASDA (bevacizumab biosimilar) has been officially approved by the National Medical Products Administration (NMPA) of China for patients with advanced non-small cell lung cancer and metastatic colorectal cancer in China.
- 30 Mar 2020 According to an Innovent Biologics Media Release, NDA approval is expected in 2020.
- 19 Sep 2019 According to an Innovent Biologics Media Release, data from this trial were presented in an oral session at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO).